CORVUS PHARMACEUTICALS INC: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei CORVUS PHARMACEUTICALS INC listata cu simbolul US.CRVS ==Descriere companie== Corvus Pharmaceuticals, Inc. (www.corvuspharma.com) is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized m...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Corvus Pharmaceuticals, Inc. (www.corvuspharma.com) is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist. | Corvus Pharmaceuticals, Inc. (www.corvuspharma.com) is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the [[A2A]] receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 30 septembrie 2024 06:09
Pagina dedicata companiei CORVUS PHARMACEUTICALS INC listata cu simbolul US.CRVS
Descriere companie[edit | ]
Corvus Pharmaceuticals, Inc. (www.corvuspharma.com) is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.
Grafic actiuni companie[edit | ]